The BRIC diabetes care devices market is estimated to grow at a CAGR of 6.3% from 2015 to 2020, to reach USD 2.3 Billion by 2020 from USD 1.7 Billion in 2015. Factors such as increasing number of diabetic patients across BRIC countries, growing research on diabetes, and increasing international research collaborations are driving the growth of the this market. Rising obese population and lifestyle changes (driving the prevalence of diabetes among the urban population) are further contributing to the growth of this market. However, high cost of diabetes care devices, disparity in reimbursement, availability of alternative treatments, and lack of awareness are restraining the growth of this market.

Know More:
https://www.marketsandmarkets.com/Market-Reports/diabetes-care-375.html

China accounted for the largest share of the BRIC diabetes care devices market; it accounted for a market share of 55.5% in 2014. Major factors driving the growth of this market in China are the rising diabetic population, increasing international collaborations, and presence of large number of diabetes care device manufacturers in the country. The Indian market, on the other hand, is expected to witness the highest CAGR, mainly due to the growing diabetic population, rapid urbanization and industrialization, and growing research on diabetes and its management.

Some of the major players operating in the BRIC diabetes care devices market are Becton, Dickinson and Company (U.S.), Roche Diagnostics Ltd. (Switzerland), Johnson and Johnson (U.S.), Bayer AG (Germany), Abbott Laboratories (U.S.), Acon Laboratories, Inc. (U.S.), Ypsomed AG (Switzerland), Novo Nordisk A/S (Denmark), Medtronic plc (Ireland), ARKRAY Inc. (Japan), Terumo Corporation (Japan), Dexcom, Inc. (U.S.), and Sanofi (France).

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownload.asp?id=375